Investing.com -- Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ: NASDAQ: MDGL) rose 17% following the announcement of their fourth-quarter and full-year 2024 financial results, which included a ...

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) reported two-year results from the open-label compensated MASH cirrhosis (F4c) ...

Madrigal Pharmaceuticals MDGL reported fourth-quarter 2024 loss of $2.71 per share, narrower than the Zacks Consensus ...

The FDA accepted odronextamab’s biologics license application resubmission for relapsed/refractory follicular lymphoma after ...

Madrigal Pharmaceuticals (MDGL) reported Q4 results and provided a 2-year update from the open-label metabolic dysfunction-associated ...

Madrigal Pharmaceuticals, Inc.'s Rezdiffra, the first approved drug for MASH, showed strong sales growth, with Q4 net sales ...

Madrigal Pharmaceuticals (MDGL) reported positive two-year results from the open-label compensated MASH cirrhosis arm of the Phase 3 ...

5Department of Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands. 6Department of Pharmaco-Therapy, -Epidemiology and- Economy, ...

The prevalence of NAFLD was 30.2% (29.8% NHW, 23.1% NHB, and 39.4% MA, P < 0.001 by race/ethnicity). The prevalence of ATP-III-defined MetS was 20.5% (20.9% NHW, 16.3% NHB, and 25.5% MA ...

Omega-3 fatty acids, found in foods like oily fish, nuts, and seeds, can extend lifespan by slowing biological aging. A study shows consuming them, along with vitamin D and exercise, rejuvenates ...

Looking forward, IMARC Group expects the 7MM to reach USD 19.1 Million by 2035, exhibiting a growth rate (CAGR) of 3 ... NAFLD market toward sustained growth. · In January 2024, Sagimet Biosciences ...